文献速递冠心病

心肌梗死的当代临床管理综述

Clinical Management of Myocardial Infarction.
PubMed 文献 · Circulation · 2026-09-14

本文是一篇最新综述,围绕心肌梗死的诊断框架、风险分层与治疗进行总结。文章重点评价了血运重建策略的时机与完全血运重建指导,以及二级预防的新兴药物治疗方法。同时特别关注了非阻塞性冠状动脉心肌梗死这一日益被认识的类型。

要点

  • 急性心肌梗死应优先及时再灌注,首选直接经皮冠状动脉介入治疗。
  • 若直接经皮冠状动脉介入治疗无法在120分钟内实施,可考虑纤溶治疗。
  • 即使传统危险因素得到控制,部分心肌梗死患者仍会复发心血管事件。

核心结论

  • 冠状动脉疾病和心肌梗死仍是全球死亡的主要原因,需要进一步优化诊断、再灌注和二级预防。

研究设计与样本

  • 本文为最新综述,总结心肌梗死的当代临床管理,并评价现有证据。

主要发现

  • 斑块破裂或侵蚀上叠加动脉粥样硬化血栓形成是心肌梗死的主要病理生理机制。
  • 斑块破坏使组织因子和内膜下成分暴露于血液,触发凝血级联和血小板聚集,最终导致腔内血栓形成。

关键数值与推荐

  • 若直接经皮冠状动脉介入治疗无法在120分钟内实施,可采用纤溶治疗。

临床怎么用

  • 应实施系统化诊疗方案,优先通过直接经皮冠状动脉介入治疗或纤溶进行立即再灌注。
  • 需关注非阻塞性冠状动脉心肌梗死的识别与管理。

局限性

  • 仍需改进闭塞性心肌梗死的风险预测和诊断流程,减少再灌注延迟,降低心源性休克相关死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite notable advancements in the acute and long-term management, coronary artery disease and myocardial infarction (MI) remain the leading cause of mortality worldwide. Atherothrombosis overlying coronary plaque rupture or erosion is the main pathophysiological mechanism of MI. Plaque disruption leads to the exposure of tissue factors and subintimal components to the luminal blood, triggering activation of the coagulation cascade and platelet aggregation, which ultimately result in luminal thrombosis. Protocolization of timely and effective revascularization in patients with acute MI is a milestone in the history of cardiovascular medicine. In the last decades, the widespread implementation of systems of care aimed at prioritizing immediate reperfusion by primary percutaneous coronary intervention or fibrinolysis (if primary percutaneous coronary intervention cannot be performed within 120 minutes), advancements in the acute phase management and secondary prevention measures has led to a substantial reduction of morbidity and mortality of MI. However, coronary artery disease and MI remains responsible for >370 000 deaths in the United States each year, and a nonnegligible proportion of patients with MI still experience recurrent cardiovascular events despite effective control of conventional risk factors. These considerations prompted the pursuit of adjunctive pharmacological agents aimed at facilitating reperfusion of the infarct-related artery and optimized secondary prevention measures to mitigate post-MI complications and residual risk for recurrent MI. This state-of-the-art review summarizes the contemporary clinical management of MI, focusing on diagnostic framework, approach to risk stratification, and treatment. A critical appraisal of the existing evidence on revascularization strategies (including timing and guidance of complete revascularization) and emerging pharmacological treatment approaches for secondary prevention of MI are also provided, with a special emphasis on the increasingly recognized entity characterized by MI without obstructive coronary artery disease. Further efforts are needed to refine risk prediction and diagnostic algorithms for occlusive MI, reduce delays to reperfusion, improve upon cardiogenic shock-related mortality, and ultimately advance adoption of secondary prevention measures that will further enhance patient outcomes.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Landi, Malik, Chieffo, et al. Clinical Management of Myocardial Infarction. Circulation. 2026. PMID: 42735223. doi:10.1161/CIRCULATIONAHA.126.079317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。